Spartalizumab
Spartalizumab
Spartalizumab (pronounced spar-ta-liz-u-mab) is a type of immunotherapy drug used in the treatment of various types of cancer. It is a monoclonal antibody that works by binding to the PD-1 receptor on T cells, thereby blocking the interaction with its ligands, PD-L1 and PD-L2. This action helps to enhance the immune response against cancer cells.
Etymology
The name "Spartalizumab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the prefix "Sparta-" does not have a specific meaning and is used for distinction.
Usage
Spartalizumab is used in the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It is administered by intravenous infusion.
Related Terms
- Immunotherapy: A type of treatment that uses the body's own immune system to fight cancer.
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Programmed cell death protein 1 (PD-1): A protein on the surface of T cells that helps to regulate the immune system's response.
- PD-L1 and PD-L2: Proteins that bind to PD-1 and can inhibit the immune response.
- T cells: A type of white blood cell that is an essential part of the immune system.
External links
- Medical encyclopedia article on Spartalizumab
- Wikipedia's article - Spartalizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski